Novartis CEO Vas Narasimhan told Bloomberg TV at Davos that the drugmaker has "future-proofed" its operations against global trade tensions. He cited a $23 billion investment in the United States as a key buffer. The remarks came during the 2026 World Economic Forum, underscoring corporate strategy amid geopolitical uncertainty.

This move reflects a broader pharmaceutical industry shift toward onshoring critical production. Major drug companies have accelerated U.S. investments since the pandemic exposed supply chain vulnerabilities and rising trade friction with China. Novartis’s pledge aims to secure its supply chain and maintain market access, a priority for investors wary of regulatory and tariff disruptions.

Narasimhan’s comments signal confidence in navigating protectionist policies without sacrificing growth. The investment, if deployed effectively, could solidify Novartis’s U.S. market position and potentially shield its stock from sector-wide volatility. Investors will watch for details on how these funds will be allocated across manufacturing and R&D facilities.